Lisa Rojkjaer, M.D. has been appointed vice president and head of clinical development at MorphoSys. Dr. Rojkjaer joins the company from Novartis Pharma, where she was most recently head of medical affairs, hematology, Europe, responsible for all clinical activities for Novartis’s hematology portfolio including Gleevec and Exjade. Prior to Novartis, she spent five years with Novo Nordisk in Copenhagen, Denmark and Princeton, NJ, as the director of global medical affairs biopharmaceuticals ...